JP6940504B2 - 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法 - Google Patents

置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法 Download PDF

Info

Publication number
JP6940504B2
JP6940504B2 JP2018531343A JP2018531343A JP6940504B2 JP 6940504 B2 JP6940504 B2 JP 6940504B2 JP 2018531343 A JP2018531343 A JP 2018531343A JP 2018531343 A JP2018531343 A JP 2018531343A JP 6940504 B2 JP6940504 B2 JP 6940504B2
Authority
JP
Japan
Prior art keywords
compound
slurry
optionally
mixture
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018531343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537495A (ja
JP2018537495A5 (enExample
Inventor
クレイグ ベイツ
クレイグ ベイツ
デービッド ピー． リード
デービッド ピー． リード
ジェンミン マオ
ジェンミン マオ
Original Assignee
アークル インコーポレイテッド
アークル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アークル インコーポレイテッド, アークル インコーポレイテッド filed Critical アークル インコーポレイテッド
Publication of JP2018537495A publication Critical patent/JP2018537495A/ja
Publication of JP2018537495A5 publication Critical patent/JP2018537495A5/ja
Priority to JP2021142864A priority Critical patent/JP2021191782A/ja
Application granted granted Critical
Publication of JP6940504B2 publication Critical patent/JP6940504B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018531343A 2015-12-17 2016-12-16 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法 Expired - Fee Related JP6940504B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142864A JP2021191782A (ja) 2015-12-17 2021-09-02 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268758P 2015-12-17 2015-12-17
US62/268,758 2015-12-17
PCT/US2016/067161 WO2017106639A1 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142864A Division JP2021191782A (ja) 2015-12-17 2021-09-02 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法

Publications (3)

Publication Number Publication Date
JP2018537495A JP2018537495A (ja) 2018-12-20
JP2018537495A5 JP2018537495A5 (enExample) 2020-01-23
JP6940504B2 true JP6940504B2 (ja) 2021-09-29

Family

ID=59057623

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018531343A Expired - Fee Related JP6940504B2 (ja) 2015-12-17 2016-12-16 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法
JP2021142864A Ceased JP2021191782A (ja) 2015-12-17 2021-09-02 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021142864A Ceased JP2021191782A (ja) 2015-12-17 2021-09-02 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法

Country Status (16)

Country Link
US (4) US9834519B2 (enExample)
EP (2) EP3390368A4 (enExample)
JP (2) JP6940504B2 (enExample)
KR (1) KR20180085814A (enExample)
CN (2) CN108602779A (enExample)
AU (2) AU2016369520B2 (enExample)
BR (1) BR112018012325A2 (enExample)
CA (1) CA3006077A1 (enExample)
EA (1) EA201891431A1 (enExample)
HK (1) HK1255014A1 (enExample)
IL (1) IL259557A (enExample)
MX (2) MX385672B (enExample)
NZ (1) NZ742785A (enExample)
SG (1) SG11201804601TA (enExample)
TW (1) TWI748972B (enExample)
WO (1) WO2017106639A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804670PA (en) * 2015-12-17 2018-07-30 Arqule Inc Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
JP6940504B2 (ja) * 2015-12-17 2021-09-29 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
US10878412B2 (en) * 2019-05-13 2020-12-29 Truist Bank In-line verification of transactions
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
MX2007007032A (es) 2004-12-17 2007-07-04 Amgen Inc Compuestos de aminopirimidina y metodos de uso.
AU2007342007A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as Axl inhibitors
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2012121764A1 (en) 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
CN106459993A (zh) * 2014-03-31 2017-02-22 德彪药业国际股份公司 Fgfr融合体
SG11201804670PA (en) 2015-12-17 2018-07-30 Arqule Inc Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
JP6940504B2 (ja) * 2015-12-17 2021-09-29 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法

Also Published As

Publication number Publication date
SG11201804601TA (en) 2018-07-30
JP2021191782A (ja) 2021-12-16
US11279679B2 (en) 2022-03-22
AU2016369520B2 (en) 2021-02-18
JP2018537495A (ja) 2018-12-20
CN114874149A (zh) 2022-08-09
AU2021202610A1 (en) 2021-05-27
WO2017106639A1 (en) 2017-06-22
US20170174637A1 (en) 2017-06-22
US20180065937A1 (en) 2018-03-08
AU2021202610B2 (en) 2022-06-02
NZ742785A (en) 2023-06-30
EP3390368A4 (en) 2019-07-03
KR20180085814A (ko) 2018-07-27
TW201733992A (zh) 2017-10-01
MX2018007415A (es) 2018-11-09
EA201891431A1 (ru) 2018-11-30
HK1255014A1 (zh) 2019-08-02
MX385672B (es) 2025-03-18
EP3390368A1 (en) 2018-10-24
AU2016369520A1 (en) 2018-06-07
CN108602779A (zh) 2018-09-28
US20190241527A1 (en) 2019-08-08
CA3006077A1 (en) 2017-06-22
US10093632B2 (en) 2018-10-09
US10766868B2 (en) 2020-09-08
MX2020012771A (es) 2022-10-04
TWI748972B (zh) 2021-12-11
BR112018012325A2 (pt) 2018-12-04
US9834519B2 (en) 2017-12-05
IL259557A (en) 2018-07-31
EP4015508A1 (en) 2022-06-22
US20200102276A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP2021191782A (ja) 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法
US20090093495A1 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
CA2998793A1 (en) Hepatitis b core protein modulators
EP4092037A1 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
TW201625618A (zh) 抑制瞬時受體電位ａ１離子通道
CN115873018B (zh) 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用
WO2020221006A1 (zh) 一种bet蛋白抑制剂、其制备方法及用途
US9206154B2 (en) Inverse agonists and neutral antagonists for the TSH receptor
US20110034498A1 (en) Dosing regimens for the treatment of cancer
TW202413326A (zh) Ｓｔａｔ３抑制劑的前藥
TW201625641A (zh) Ｎａｍｐｔ抑制劑及方法
CN107827837B (zh) 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
US20230056497A1 (en) CD206 Modulators Their Use and Methods for Preparation
US20200147039A1 (en) Compounds useful in inhibiting human trefoil factor 3
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
HK40079039A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
US20240317717A1 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
CN107286057A (zh) 间苯二酚类化合物及医药用途
EA042753B1 (ru) Способы получения полиморфа дигидрохлорида замещенного 5,6-дигидро-6-фенилбензо[f]изохинолин-2-амина
HK1244276B (zh) 用於治疗hiv的稠合嘧啶化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210902

R150 Certificate of patent or registration of utility model

Ref document number: 6940504

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees